Emergent BioSolutions (NYSE:EBS) Rating Reiterated by JPMorgan Chase & Co.

Emergent BioSolutions (NYSE:EBS – Get Rating)‘s stock had its “underweight” rating reiterated by research analysts at JPMorgan Chase & Co. in a note issued to investors on Friday, Marketbeat reports. They presently have a $9.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $23.00. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 10.84% from the company’s current price.

Several other equities analysts have also recently issued reports on EBS. TheStreet cut Emergent BioSolutions from a “c-” rating to a “d” rating in a report on Monday, February 27th. StockNews.com assumed coverage on Emergent BioSolutions in a report on Thursday. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $31.20.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $8.12 on Friday. Emergent BioSolutions has a twelve month low of $8.11 and a twelve month high of $45.14. The firm has a market cap of $407.14 million, a PE ratio of -1.81 and a beta of 0.94. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.70 and a current ratio of 0.98. The business has a fifty day moving average of $12.82 and a 200-day moving average of $15.50.

Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.62). The firm had revenue of $330.70 million during the quarter, compared to the consensus estimate of $298.23 million. Emergent BioSolutions had a negative net margin of 19.97% and a negative return on equity of 7.57%. Emergent BioSolutions’s revenue was down 54.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.50 EPS. On average, equities research analysts predict that Emergent BioSolutions will post -1.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. Gladius Capital Management LP raised its position in shares of Emergent BioSolutions by 96.8% during the fourth quarter. Gladius Capital Management LP now owns 3,113 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,531 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Emergent BioSolutions during the fourth quarter worth about $56,000. High Net Worth Advisory Group LLC acquired a new stake in shares of Emergent BioSolutions during the third quarter worth about $63,000. Covestor Ltd raised its position in shares of Emergent BioSolutions by 43.8% during the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 491 shares during the period. Finally, Ancora Advisors LLC acquired a new stake in shares of Emergent BioSolutions during the first quarter worth about $66,000. Institutional investors own 80.44% of the company’s stock.

About Emergent BioSolutions

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.